clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Bacterial Infections D001424 21 associated lipids
Bacteriuria D001437 7 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Body Weight D001835 333 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Bradycardia D001919 13 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Bronchitis D001991 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Chlamydia Infections D002690 7 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Colitis D003092 69 associated lipids
Confusion D003221 4 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Cross Infection D003428 9 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cysts D003560 4 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatomycoses D003881 17 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Diphtheria D004165 2 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenitis D004382 4 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Dyspepsia D004415 5 associated lipids
Dyspnea D004417 10 associated lipids
Ecchymosis D004438 3 associated lipids
Empyema D004653 3 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Hoffman JS Pharmacological therapy of Helicobacter pylori infection. 1997 Semin. Gastrointest. Dis. pmid:9232728
Terkeltaub RA Colchicine update: 2008. 2009 Semin. Arthritis Rheum. pmid:18973929
Moskowitz RW et al. Open-label study of clarithromycin in patients with undifferentiated connective tissue disease. 2006 Semin. Arthritis Rheum. pmid:17023256
Mateo L et al. Mycobacterium chelonae tenosynovitis of the hand. 2004 Semin. Arthritis Rheum. pmid:15609266
Liang J et al. [Analysis of the key intermediates for the regioselectivity control in the methylation of the manufacture of clarithromycin by reversed-phase high performance liquid chromatography]. 2004 Se Pu pmid:15712906
Velu PP et al. Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. 2016 Scott Med J pmid:27872397
Cadwgan AM et al. Neisseria meningitidis W135 pneumonia with sepicaemia in a nonogenarian. 1998 Scott Med J pmid:9854302
Isidori M et al. Toxic and genotoxic evaluation of six antibiotics on non-target organisms. 2005 Sci. Total Environ. pmid:15993685
Göbel A et al. Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies. 2007 Sci. Total Environ. pmid:17126383
Buchicchio A et al. Biodegradation of carbamazepine and clarithromycin by Trichoderma harzianum and Pleurotus ostreatus investigated by liquid chromatography - high-resolution tandem mass spectrometry (FTICR MS-IRMPD). 2016 Sci. Total Environ. pmid:27039063
Al Aukidy M et al. Monitoring release of pharmaceutical compounds: occurrence and environmental risk assessment of two WWTP effluents and their receiving bodies in the Po Valley, Italy. 2012 Sci. Total Environ. pmid:22967493
Topp E et al. Reduced persistence of the macrolide antibiotics erythromycin, clarithromycin and azithromycin in agricultural soil following several years of exposure in the field. 2016 Sci. Total Environ. pmid:27096634
Spongberg AL and Witter JD Pharmaceutical compounds in the wastewater process stream in Northwest Ohio. 2008 Sci. Total Environ. pmid:18396321
Feng L et al. Removal of antibiotics during the anaerobic digestion of pig manure. 2017 Sci. Total Environ. pmid:28628813
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Bruhn DF et al. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. 2015 Sci Rep pmid:26365087
Vliegenthart AD et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. 2015 Sci Rep pmid:26489516
Arora S et al. Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for h. Pylori. Sci Pharm pmid:21886911
Kobler E et al. [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. 1997 Schweiz Med Wochenschr Suppl pmid:9289833
Sieber CC et al. [Helicobacter pylori resistance against metronidazole in Switzerland: implications for eradication therapy?]. 1994 Schweiz Med Wochenschr pmid:8091165
Lõivukene K et al. Metronidazole and clarithromycin susceptibility and the subtypes of vacA of Helicobacter pylori isolates in Estonia. 2000 Scand. J. Infect. Dis. pmid:10716079
Edlund C et al. Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. 2000 Scand. J. Infect. Dis. pmid:10716083
Dionisio D et al. Encephalitis caused directly by Mycoplasma pneumoniae. 1999 Scand. J. Infect. Dis. pmid:10576133
Hakawi AM and Alrajhi AA Septic arthritis due to Mycobacterium szulgai in a patient with human immunodeficiency virus: case report. 2005 Scand. J. Infect. Dis. pmid:15849060
Barzilai A et al. Successful treatment of disseminated Mycobacterium simiae infection in AIDS patients. 1998 Scand. J. Infect. Dis. pmid:9730300
Davies BS et al. Non-tuberculous slow-growing mycobacterial pulmonary infections in non-HIV-infected patients in south London. 2012 Scand. J. Infect. Dis. pmid:23078529
Inoue H et al. Modulation of the human interleukin-12p40 response by a triazole antifungal derivative, itraconazole. 2004 Scand. J. Infect. Dis. pmid:15370674
Kiiveri KM et al. Recurrent endocarditis caused by beta-haemolytic streptococci group B. 2004 Scand. J. Infect. Dis. pmid:15307575
Jakobsson H et al. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. 2007 Scand. J. Infect. Dis. pmid:17701712
Cordtz J and Jensen JS Disseminated Ureaplasma urealyticum infection in a hypo-gammaglobulinaemic renal transplant patient. 2006 Scand. J. Infect. Dis. pmid:17148091
Bodasing N and Kennedy D Moraxella catarrhalis bacteraemia associated with Mycoplasma pneumoniae infection and pneumonia. 2002 Scand. J. Infect. Dis. pmid:12578160
Giamarellos-Bourboulis E et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. 2005 Scand. J. Infect. Dis. pmid:15764190
Burkhardt O et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. 2002 Scand. J. Infect. Dis. pmid:12587622
Ghebremichael S et al. Antimycobacterial synergism of clarithromycin and rifabutin. 1996 Scand. J. Infect. Dis. pmid:8893404
Nakamura S et al. Community acquired pneumonia (CAP) caused by Cryptococcus neoformans in a healthy individual. 2005 Scand. J. Infect. Dis. pmid:16308237
Trübel HK et al. Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child. 2002 Scand. J. Infect. Dis. pmid:12030402
Alfakry H et al. Periodontopathogen- and host-derived immune response in acute coronary syndrome. 2011 Scand. J. Immunol. pmid:21645027
Alfakry H et al. The association of serum neutrophil markers and acute coronary syndrome. 2012 Scand. J. Immunol. pmid:22537345
Götz JM et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. 1995 Scand. J. Gastroenterol. Suppl. pmid:8578230
Williamson R et al. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. 1998 Scand. J. Gastroenterol. Suppl. pmid:9515751
Unge P Review of Helicobacter pylori eradication regimens. 1996 Scand. J. Gastroenterol. Suppl. pmid:8722388
Bazzoli F Italian omeprazole triple therapy--a 1-week regimen. 1996 Scand. J. Gastroenterol. Suppl. pmid:8722395
Giorgio F et al. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. 2016 Scand. J. Gastroenterol. pmid:27687850
Ochi M et al. Regression of primary low-grade mucosa-associated lymphoid tissue lymphoma of duodenum after long-term treatment with clarithromycin. 2006 Scand. J. Gastroenterol. pmid:16497629
Testoni PA and Bagnolo F In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern. 2000 Scand. J. Gastroenterol. pmid:10994618
Gisbert JP et al. Unhealed duodenal ulcers despite Helicobacter pylori eradication. 1997 Scand. J. Gastroenterol. pmid:9246702
Parente F et al. Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study. 1998 Scand. J. Gastroenterol. pmid:9648983
Tsukada K et al. Seven-day triple therapy with omeprazole, amoxycillin and clarithromycin for Helicobacter pylori infection in haemodialysis patients. 2002 Scand. J. Gastroenterol. pmid:12465723
Murakami K et al. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. 2011 Scand. J. Gastroenterol. pmid:21073372